{"schema_version":"1.0","type":"article","title":"Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events?","url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon-en.md","lang":"en","date":"2026-07-29","publish_at":"2026-07-29T08:00:00+08:00","updated_at":"2026-07-29","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","pelacarsen","Lp(a)","HORIZON","cardiovascular disease","clinical trials","antisense oligonucleotide","Novartis","Ionis","biotech investing"],"summary":"Pelacarsen can substantially lower Lp(a), but HORIZON must show whether biomarker reduction on top of standard care translates into fewer cardiovascular deaths, myocardial infarctions, strokes and urgent revascularizations.","key_points":[],"facts":[],"sections":["01 | Why Lp(a) and LDL-C Are Not the Same Problem","02 | Pelacarsen Has Shown That It Can Lower Lp(a), Not Yet That It Can Prevent Events","03 | The Trial Design Determines How the Result Should Be Read","04 | When the Result Arrives, Do Not Stop at “Met” or “Missed”","05 | Why One Readout Could Reprice the Entire Lp(a) Field","06 | What Taiwan Readers Should Watch","Conclusion | The Test Is Not Whether Pelacarsen Lowers a Number","References"],"references":[{"title":"[ClinicalTrials.gov","source":"NCT04023552, Lp(a) HORIZON]","date":"","url":"https://clinicaltrials.gov/study/NCT04023552"},{"title":"[Novartis","source":"Q1 2026 investor presentation]","date":"","url":"https://www.novartis.com/sites/novartis_com/files/q1-2026-investor-presentation.pdf"},{"title":"[Ionis","source":"First-quarter 2026 financial results]","date":"","url":"https://ir.ionis.com/news-releases/news-release-details/ionis-reports-first-quarter-2026-financial-results-and"},{"title":"[American Heart Journal","source":"HORIZON design and rationale, PMID 40185318]","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/40185318/"},{"title":"[New England Journal of Medicine","source":"Pelacarsen phase 2, PMID 31893580]","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/31893580/"},{"title":"[ClinicalTrials.gov","source":"OCEAN(a)-Outcomes, NCT05581303]","date":"","url":"https://clinicaltrials.gov/study/NCT05581303"},{"title":"[ClinicalTrials.gov","source":"ACCLAIM-Lp(a), NCT06292013]","date":"","url":"https://clinicaltrials.gov/study/NCT06292013"},{"title":"[ClinicalTrials.gov","source":"MOVE-Lp(a), NCT07157774]","date":"","url":"https://clinicaltrials.gov/study/NCT07157774"}],"images":[{"alt":"HORIZON must establish whether lowering Lp(a) reduces cardiovascular events, not merely whether the biomarker falls","url":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/figure-01.webp"},{"alt":"Pelacarsen reduces apo(a) production and Lp(a), while the connection to fewer cardiovascular events remains to be proven","url":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/figure-02.webp"},{"alt":"A five-layer framework for reading HORIZON: hypothesis, effect size, endpoint composition, biomarker linkage and long-term burden","url":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/figure-03.webp"},{"alt":"Four checks for Taiwan readers: population, measurement units, local access and direct investment evidence","url":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/figure-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/homepage-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-29）。Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events?。https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-19-pelacarsen-lpa-horizon.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}